Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00649909|
Recruitment Status : Completed
First Posted : April 1, 2008
Last Update Posted : August 10, 2017
The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes.
We will perform an observational study where we follow up patients with uncontrolled type 2 Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6 months in the diabetic clinic. Our hypothesis is that glucose control will improve the response to aspirin in those patients.
|Condition or disease|
|Diabetes Mellitus, Type II|
|Study Type :||Observational|
|Actual Enrollment :||18 participants|
|Official Title:||Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||November 2010|
|Actual Study Completion Date :||November 2010|
Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
- The outcome measure is the laboratory Aspirin Resistance. [ Time Frame: 3 and 6 months. ]
- To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors. [ Time Frame: On screening visit. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00649909
|Hadassah Medical Organization|
|Principal Investigator:||David Varon, MD||Hematology Department, Hadassah Medical Organization, Jerusalem, Israel|